Keyphrases
Adaptive Immune Response
50%
AECII
50%
Airway
50%
Airway Inflammation
50%
Alveolar Epithelial
50%
Anti-inflammatory Drugs
100%
Asthma
50%
Basal Level
50%
Chlorambucil
100%
Chloroquine
100%
Chronic Injury
50%
Chronic Obstructive Pulmonary Disease
50%
Clinical Characteristics
50%
Clinical Data
50%
D-penicillamine
100%
Disease-based
50%
Epithelial Homeostasis
50%
Epithelial Injury
50%
Epithelial Phenotype
50%
Excessive Apoptosis
50%
Idiopathic Pulmonary Fibrosis
100%
Immune Defense
50%
Immunomodulatory Effect
50%
Inflammation
50%
Inflammatory Cells
50%
Inflammatory Mediators
50%
Innate Immune Response
50%
Interstitial Lung Disease
100%
Life-threatening
50%
Mechanism of Action
50%
Narrow Therapeutic Index
50%
Pathophysiology
50%
Paucity
50%
Pirfenidone
100%
Preclinical Development
50%
Pulmonary Disease
100%
Randomized Clinical Trial
50%
Respiratory Disease
100%
Treatment Modalities
50%
Medicine and Dentistry
Antiinflammatory Agent
100%
Asthma
50%
Chlorambucil
100%
Chloroquine
100%
Chronic Obstructive Pulmonary Disease
50%
Homeostasis
50%
Idiopathic Pulmonary Fibrosis
100%
Inflammatory Cell
50%
Inflammatory Mediator
50%
Injury
100%
Interstitial Lung Disease
100%
Pathophysiology
50%
Penicillamine
100%
Pirfenidone
100%
Pre-Clinical Development
50%
Programmed Cell Death
50%
Randomized Clinical Trial
50%
Respiratory Disease
100%
Respiratory Tract Inflammation
50%
Side Effect
100%
Silo-Filler's Disease
100%
Therapeutic Window
50%
Pharmacology, Toxicology and Pharmaceutical Science
Antiinflammatory Agent
100%
Asthma
50%
Chlorambucil
100%
Chloroquine
100%
Chronic Obstructive Lung Disease
50%
Fibrosing Alveolitis
100%
Inflammation
50%
Injury
100%
Interstitial Lung Disease
100%
Lung Disease
100%
Pathophysiology
50%
Penicillamine
100%
Pirfenidone
100%
Randomized Clinical Trial
50%
Respiratory Tract Disease
100%
Respiratory Tract Inflammation
50%
Side Effect
100%
Therapeutic Window
50%